DFA(DFA) - 在研适应症：黄热病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

7-Deaza-7-Fluoro-2′-C-Methyladenosine

靶点-

作用方式-

作用机制-

治疗领域

感染其他疾病

在研适应症

黄热病

非在研适应症-

原研机构

Emory University School of Medicine

在研机构

Emory University School of Medicine

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构/序列

分子式C12H15FN4O4

InChIKeyYOAGQSGRMBEQCY-YUTYNTIBSA-N

CAS号443643-17-2

关联

100 项与 DFA 相关的临床结果

登录后查看更多信息

100 项与 DFA 相关的转化医学

登录后查看更多信息

100 项与 DFA 相关的专利（医药）

登录后查看更多信息

209

项与 DFA 相关的文献（医药）

2025-05-07·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combating yellow fever virus with 7-deaza-7-fluoro-2′-C-methyladenosine

Article

作者: Rezaei, Sahar ; Lee, Sujin ; Zandi, Keivan ; Goncalves, Matheus Rodrigues ; Rust, Lauren N. ; Patel, Dharmeshkumar ; Teixeira, Mauro M. ; Queroz-Junior, Celso Martins ; Salman, Mohammad ; Marim, Fernanda Martins ; Burwitz, Benjamin ; LeCher, Julia C. ; McBrayer, Tamara ; Moua, Justin ; Amblard, Franck ; Azadi, Niloufar ; Zhou, Longhu ; De, Ramyani ; Bassit, Leda C. ; Costa, Vivian Vasconcelos ; Santos, Felipe Rocha da Silva ; Schinazi, Raymond F.

ABSTRACT:

Yellow fever virus (YFV) is a deadly zoonotic flavivirus endemic in tropical/sub-tropical Africa and South America transmitted by mosquito vector ( Aedes aegypti ; Haemagogus leucocelaenus ) to humans and non-human primates. There are no approved antiviral agents for YFV. We previously identified 7-deaza-7-fluoro-2′-C-methyladenosine (DFA) with anti-YFV activity. Interestingly, DFA exhibits pan-activity in vitro against flaviviruses, such as dengue, Japanese encephalitis, Zika, and hepatitis C. This study aimed to expand DFA’s anti-flavivirus profile. DFA exhibited potent sub-micromolar anti-YFV activity in vitro against both the vaccine strain (YFV-17D) and a viscerotropic clinical YFV isolate (DakH1279) concomitantly with low cellular cytotoxicity and no notable mitochondrial toxicity. In vivo , efficacy was assessed against both YFV-17DD and a human clinical isolate in A129 and AG129 mouse flavivirus infection models, respectively. DFA significantly reduced virus replication in the livers of YFV-infected mice and the hallmarks of YFV-induced liver damage, including alanine transaminase levels and indocyanine green clearance. Collectively, this work identifies DFA as a potent YFV inhibitor and lays the groundwork for further therapeutic development as a YFV and, potentially, pan-flavivirus therapeutic.

2025-04-01·VASCULAR MEDICINE

Outcomes of contemporary stents with deep femoral artery coverage

Article

作者: Kojima, Shunsuke ; Ogata, Kenji ; Tokuda, Takahiro ; Takei, Tatsuro ; Yamaguchi, Kohei ; Yanagiuchi, Takashi ; Nakama, Tatsuya ; Tanaka, Akiko ; Yoshioka, Naoki

Introduction::

We aimed to investigate deep femoral artery (DFA) status during endovascular treatment (EVT) and the patency of the femoropopliteal (FP) artery and DFA using current stent devices for ostial FP lesions.

Methods::

A multicenter, retrospective study analyzed data from 457 patients who underwent EVT with stent deployment for de novo ostial FP lesions between April 2018 and December 2021 at eight centers in Japan. Propensity score-matched analysis was performed to compare the clinical impacts of DFA coverage for ostial FP lesions with stent deployment. The prognostic value was analyzed based on DFA status during EVT, primary patency of the FP artery, clinically driven-target lesion revascularization (CD-TLR) of the FP artery, and incidence of DFA occlusion/major amputation/acute limb ischemia (ALI) at 3 years.

Results::

A total of 132 matched pairs of patients was analyzed using propensity score matching. The percentage of DFA occlusion and stenosis was significantly higher in the DFA coverage group. However, there were no significant differences in terms of primary patency of the FP artery, CD-TLR, DFA occlusion, major amputation, or ALI after 3 years.

Conclusions::

Stent deployment in DFA coverage significantly led to the DFA stenotic events of EVT during the procedure, but patency of the FP artery and DFA, major amputation, and ALI up to 3 years did not differ according to stent deployment for ostial FP lesions.

2025-01-01·JOURNAL OF MEDICAL INVESTIGATION

Effects of zinc supplementation in combination with difructose, an enhancer of intestinal zinc absorption, on serum zinc concentration and ratio of apo-/holo-activities of angiotensin-converting enzyme in patients with refractory taste impairment

Article

作者: Tsutsumi, Rie ; Kitamura, Yoshiaki ; Takaoka, Tsukasa ; Sakaue, Hiroshi ; Takemoto, Ichiko ; Takeda, Noriaki ; Endo, Aki

OBJECTIVE:

ACE ratio in the serum is a more sensitive indicator of zinc nutrition than serum zinc concentration. In this study, we examined the effects of zinc supplementation in combination with difructose anhydride (DFA) that enhances zinc absorption in the intestine on serum zinc concentration and ACE ratio in patients with refractory taste impairment.

METHODS:

Twenty patients with refractory taste impairment were enrolled. The patients received 34 mg of zinc in combination with 2.0 g of DFA orally every day for three months. Taste impairment was evaluated using visual analogue scale (VAS).

RESULTS:

After zinc supplementation with DFA (zinc with DFA), ACE ratio was significantly decreased, but serum zinc concentration was not increased in patiens with refractory taste impairment. Although VAS score was not changed in the patients after zinc with DFA, we divided the patients into two groups : 14 responders and 6 non-responders. ACE ratio in responders, but not in non-responders was significantly decreased after zinc with DFA. However, serum zinc concentration was not changed in both responders and non-responders after zinc with DFA.

CONCLUSION:

The present findings suggest that malabsorption of zinc in the intestine is the primary cause of zinc deficiency in patients with refractory taste impairment. J. Med. Invest. 72 : 156-160, February, 2025.

100 项与 DFA 相关的药物交易

登录后查看更多信息